Who are RAMIPRIL HOE498's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vasotec, Lercanidipine/enalapril fixed combination, ACEI treatment, Renin-Angiotensin (RAAS) alone, ACEI/ARB, ACEI continuation.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ramipril-hoe498.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

RAMIPRIL HOE498 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RAMIPRIL HOE498 (RAMIPRIL HOE498) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor. Area: Cardiovascular.

marketed ACE inhibitor Angiotensin-converting enzyme (ACE) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

RAMIPRIL HOE498 (RAMIPRIL HOE498) — Sanofi. Ramipril inhibits angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RAMIPRIL HOE498 TARGET	RAMIPRIL HOE498	Sanofi	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)
Vasotec	enalapril	Merck & Co.	marketed	ACE inhibitor	Angiotensin-converting enzyme, Angiotensin-converting enzyme	1985-12-24
Lercanidipine/enalapril fixed combination	Lercanidipine/enalapril fixed combination	Meir Medical Center	marketed	Calcium channel blocker / ACE inhibitor combination	L-type voltage-gated calcium channels; Angiotensin-converting enzyme (ACE)
ACEI treatment	ACEI treatment	Children's Hospital of Fudan University	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)
Renin-Angiotensin (RAAS) alone	Renin-Angiotensin (RAAS) alone	James A. Tumlin, MD	marketed	RAAS inhibitor (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist)	Renin-angiotensin-aldosterone system components (ACE, AT1 receptor, renin, or aldosterone receptor)
ACEI/ARB	ACEI/ARB	Capital Institute of Pediatrics, China	marketed	ACE inhibitor / Angiotensin II receptor blocker	ACE enzyme / Angiotensin II type 1 receptor (AT1R)
ACEI continuation	ACEI continuation	University of Nebraska	marketed	ACE inhibitor	Angiotensin-converting enzyme (ACE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor class)

Boryung Pharmaceutical Co., Ltd · 5 drugs in this class
Bioprojet · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class
Beijing Tide Pharmaceutical Co., Ltd · 1 drug in this class
Children's Hospital of Fudan University · 1 drug in this class
Ache Laboratorios Farmaceuticos S.A. · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
Ethicare GmbH · 1 drug in this class
Ace Cells Lab Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RAMIPRIL HOE498 — Competitive Intelligence Brief. https://druglandscape.com/ci/ramipril-hoe498. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing